1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Esclerosis Múltiple

Esclerosis Múltiple

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • González-Gay MÁ, Gómez-Bernal F, Heras-Recuero E, Quevedo-Abeledo JC, Torres-Roselló A, Almeida-Santiago C, de Vera-González A, Tejera-Segura B, Blázquez-Sánchez T, García-Barrera E, Villar LM, Ocejo-Vinyals JG, Largo R, Ferraz-Amaro I.

    High-sensitivity serum interferon-a and interferon-? as immunometabolic mediators of metabolic syndrome in systemic lupus erythematosus.

    RHEUMATOLOGY . 65(5): .

    [doi:10.1093/rheumatology/keag235]

  • García Domínguez JM, María Villar L, Arrambide G, Blanco Y, Carmen Calles M, Casanova B, Castillo-Triviño T, Costa-Frossard França L, Eichau S, Hernández Pérez MÁ, Landete L, Meca Lallana J, Oreja-Guevara C, María Prieto J, Querol L, Belén Caminero A.

    Relevance of serum neurofilament light chain determination as a biomarker in multiple sclerosis. Consensus of the Spanish Society of Neurology's Study Group on Multiple Sclerosis and Related Neuroimmune Diseases.

    Neurologia . 41(4): 501928-501928.

    [doi:10.1016/j.nrleng.2026.501928]

  • Miguela A, Huertas-Pons JM, Coll-Martinez C, Gifreu-Fraixinó A, Salavedra-Pont J, Comabella M, Villar LM, Gich J, Álvarez-Bravo G, Ramió-Torrentà L, Quiroga-Varela A.

    A glial oxidative signature predicts disability in primary progressive multiple sclerosis and is associated with long-term cognitive decline.

    Frontiers in Immunology . 17: 1802339-1802339.

    [doi:10.3389/fimmu.2026.1802339]

  • León-Cabrera D, Quevedo-Abeledo JC, Almeida-Santiago C, García-Barrera E, Villar LM, Quiroga-Colina P, Ocejo-Vinyals JG, Javier-Ormazábal A, González-Gay MÁ, Ferraz-Amaro I.

    Serum interleukin-8 levels relate to disease activity in patients with rheumatoid arthritis.

    Therapeutic Advances in Musculoskeletal Disease . 18: .

    [doi:10.1177/1759720X261436835]

  • Saposnik G, Solanes A, Monreal E, Sepúlveda M, Hernández MÁ, Cuello JP, Álvarez-Bravo G, Agüera-Morales E, Riancho J, Pérez-Sempere Á, Maurino J, Gómez-Ballesteros R.

    Large language models as clinical decision-support tools in multiple sclerosis and neuromyelitis optica spectrum disorders: A comparative study of ChatGPT-4o and neurologists.

    Multiple Sclerosis Journal-Experimental Translational and Clinical . 12(2): .

    [doi:10.1177/20552173261438268]

  • Macia-Villa C, Fernández-Velasco JI, Ferre-Sanfrancisco M, Mendoza-Bravo DA, Ruiz-Bejerano AM, Ferrez-Hernández C, Morell-Hita JL.

    HLA-Cw6 in Psoriatic Arthritis: Clinical Phenotype and Therapeutic Impact.

    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY . 32(3): 79-84.

    [doi:10.1097/RHU.0000000000002322]

  • Pérez-Sempere Á, García-Arcelay E, Pérez JC, Candeliere-Merlicco A, Orviz A, Martín-Martínez J, Piñar-Morales R, Álvarez-Rodríguez E, Pacheco-Cortegana EM, Borrega L, Casanova I, Caminero AB, Sánchez-Menoyo JL, Gómez-Gutiérrez M, Carmona O, Calles C, Hernández MÁ, López-Muñoz P, Bakdache F, Monreal E, González-Suárez I, Maurino J.

    Personalizing Relapsing-Remitting Multiple Sclerosis Monitoring: Patient Acceptance of Serum Neurofilament Light Chain and the Role of Disease Knowledge.

    Journal of Personalized Medicine . 16(4): .

    [doi:10.3390/jpm16040185]

  • Dominguez-Mozo MI, Ruberto S, Rodríguez-García C, Villar LM, Costa-Frossard L, Villarrubia N, Aladro Y, Casanova-Peño I, Martínez-Ginés ML, García-Domínguez JM, Ortega-Madueño I, Alonso-Garrido A, Pérez de Villar G, Garcia-Martinez MA, Arroyo R, Alvarez-Lafuente R.

    Differential distribution of antiviral serology across multiple sclerosis phenotypes and its implications for disease pathogenesis.

    Scientific Reports . 16(1): .

    [doi:10.1038/s41598-026-46208-3]

  • Ruberto S, Dominguez-Mozo MI, Villar LM, Costa-Frossard L, Villarrubia N, Aladro Y, Casanova-Peño I, González-Suárez I, Garcia-Martinez MA, Arroyo R, Alvarez-Lafuente R.

    HERV-W association with serum biomarkers NfL and GFAP in multiple sclerosis.

    Frontiers in Immunology . 17: 1776117-1776117.

    [doi:10.3389/fimmu.2026.1776117]

  • Benito-León J, Díez-Cirarda M, Ruiz-Ortiz M, Aladro Y, Cuevas C, Domingo-Santos Á, Galán Sánchez-Seco V, Labiano-Fontcuberta A, Gómez-López A, Salgado-Cámara P, Costa-Frossard L, Monreal E, Sainz de la Maza S, Matías-Guiu J, Montero-Escribano P, Martínez-Ginés ML, Ayuso-Peralta L, Matías-Guiu JA.

    Health-Related Quality of Life in Radiologically Isolated Syndrome Resembles Relapsing-Remitting Multiple Sclerosis.

    Journal of Clinical Medicine . 15(6): .

    [doi:10.3390/jcm15062184]

  • Gonzalez-Gay MÁ, Gómez-Bernal F, Tejera-Segura B, Quevedo-Abeledo JC, García-Barrera E, Villar LM, Ocejo-Vinyals JG, Largo R, Ferraz-Amaro I.

    Serum IL-2 levels are associated with disease activity and related to dyslipidaemia and the immunological profile in systemic lupus erythematosus.

    Lupus Science & Medicine . 13(1): .

    [doi:10.1136/lupus-2025-001870]

  • Gómez-Bernal F, Quevedo Abeledo JC, Almeida-Santiago C, Fernández-Cladera Y, García-Barrera E, Villar LM, Largo R, Ocejo-Vinyals JG, González-Gay MÁ, Ferraz-Amaro I.

    Clinical and serological associations of interferon-a and interferon-? in rheumatoid arthritis patients.

    RHEUMATOLOGY . 65(2): . Nº de citas: 2

    [doi:10.1093/rheumatology/keag036]

  • Comabella M, Gutierrez L, Castillo M, Villar LM, Eixarch H, La Puma D, Aroca M, Vilaseca A, Montalban X, Fissolo N.

    Impact of preanalytical factors on blood CHI3L1 levels.

    Frontiers in Immunology . 16: 1720914-1720914. Nº de citas: 1

    [doi:10.3389/fimmu.2025.1720914]

  • Fissolo N, Benkert P, Vilaseca-Jolonch A, Blanco Y, Hegen H, Berek K, Pérez-Miralles F, Rejdak K, Villar L, Monreal E, Alvarez-Lafuente R, Bachhuber F, Tumani H, Martínez-Yelamos S, Sánchez-López A, García-Merino A, Gutiérrez L, Castillo-Triviño T, Lycke J, Rosenstein I, Téllez N, Furlan R, Lünemann JD, Khalil M, Kuhle J, Montalban X, Comabella M.

    Serum sTREM2 Levels and Disability Progression in Patients With Primary Progressive Multiple Sclerosis.

    EUROPEAN JOURNAL OF NEUROLOGY . 33(2): . Nº de citas: 1

    [doi:10.1111/ene.70480]

  • Fernández Ó, Arés A, Agüera E, Aladro Y, Alonso A, Arroyo R, Brieva L, Calles C, Caminero AB, Castillo-Triviño T, Costa-Frossard L, Eichau S, Hernández MÁ, Landete L, Llaneza M, Llufriu S, Meca-Lallana JE, Meca-Lallana V, Moral E, Oreja-Guevara C, Prieto JM, Romero-Pinel L, Vilaseca A, Rodríguez-Antigüedad A.

    XVII Reunión Post-ECTRIMS: Revisión de las Novedades Presentadas en el Congreso ECTRIMS 2024 (Parte I).

    REVISTA DE NEUROLOGIA . 81(1): 39227-39227.

    [doi:10.31083/RN39227]

  • Fernández Ó, Arés A, Agüera E, Aladro Y, Alonso A, Arroyo R, Brieva L, Calles C, Caminero AB, Castillo-Triviño T, Costa-Frossard L, Eichau S, Hernández MÁ, Landete L, Llaneza M, Llufriu S, Meca-Lallana JE, Meca-Lallana V, Moral E, Oreja-Guevara C, Prieto JM, Romero-Pinel L, Vilaseca A, Rodríguez-Antigüedad A.

    XVII Reunión Post-ECTRIMS: Revisión de las Novedades Presentadas en el Congreso ECTRIMS 2024 (Parte II).

    REVISTA DE NEUROLOGIA . 81(1): 39228-39228.

    [doi:10.31083/RN39228]

  • García de la Torre I, García-Hoz C, Martin-Moro F, Fernández-Velasco JI, Velázquez-Kennedy K, Rodríguez-Martín E, Luna De Abia A, Roldán E, Moreno Jiménez G, López-Jiménez J, Villar LM, Pariente-Rodríguez R.

    Apheresis CD8(+)CCR7(+)CD45RA(-) T-Cells as a Novel Biomarker Associated with CAR T-Cell Kinetics and Clinical Outcome.

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES . 27(2): . Nº de citas: 1

    [doi:10.3390/ijms27020866]

  • Martín-Pedraza L, Rodríguez-Martín E, De La Torre-Tarazona E, Moreno E, Pariente-Rodríguez R, Walo-Delgado PE, García-Pérez J, Díaz J, Luna L, Rodríguez-Dominguez M, Galán JC, Geraldine Rita C, Del Amo-de Palacios A, Navarro-Soler R, Fons M, Alcamí J, Moreno S, Villar LM, Serrano-Villar S.

    Contrasting immune responses in COVID-19: insights from healthcare workers and infected patients on plasmablast, pDC, and NK cell dynamics.

    Frontiers in Immunology . 16: 1693903-1693903. Nº de citas: 2

    [doi:10.3389/fimmu.2025.1693903]